A deeper dive into data from the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) with the type 2 diabetes drug sitagliptin, confirming that the dipeptidyl peptidase-4 (DPP-4) is not associated with any risk of developing heart failure in diabetic patients at high cardiovascular risk, has been published in JAMA Cardiology . "Overall, this is very reassuring data for sitagliptin," says cardiologist who is a MD, MPH, of a Medical School in Boston, Massachusetts, writing in an accompanying editorial.
These results from TECOS were first reported at the European Society of Cardiology meeting last September in London and represent a prespecified secondary analysis of the overall TECOS study, the findings of which were presented at the American Diabetes Association conference in June 2015. These newly published data, by cardiologist who is a MD of a University in Dallas, and…
